Voglichew 0.2 Tablet MD

产品概览

About Voglichew 0.2 Tablet MD

Voglichew 0.2 Tablet MD is a medication containing the active ingredient Voglibose, classified as Alpha-glucosidase inhibitor. Voglibose is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company.

Key Benefits & Uses

• Used for: Voglibose is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus
• Used for: Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company
• Use only as directed on the product label or by a healthcare professional.

Active Ingredient & Action

Voglibose, the active ingredient in Voglichew 0.2 Tablet MD, belongs to the Alpha-glucosidase inhibitor class. Its clinical use follows the authorised labelling for Voglibose-containing medicines. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking Voglichew 0.2 Tablet MD. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Voglichew 0.2 Tablet MD for extended periods without medical advice.